Powered by
-
REGN Stock Chart
Historical REGN Prices
Regeneron Pharmaceuticals Stock Analysis
Rating: Hold
Total Grade: C
Analysis Breakdown
| REGN Stock Grade: | C |
| Fundamental Grade: | B |
| Quantitative Grade: | D |
| REGN Earnings | |
| Earnings Growth: | B |
| Earnings Momentum: | F |
| Earnings Surprises: | B |
| Analyst Earnings Revisions: | A |
| REGN Financial Information | |
| Sales Growth: | C |
| Operating Margin Growth: | B |
| Cash Flow: | B |
| Return on Equity: | A |
Regeneron Pharmaceuticals Stock: Weekly View
| This Week: | C |
|---|---|
| Last Week: | D |
| Two Weeks Ago: | D |
REGN Stock predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
-
5 Healthcare Stocks to Buy for Complete Portfolio Wellness - October 10, 2018
Thanks to advancing technologies and a generally positive economy, healthcare stocks are back in the limelight. Continue…
-
5 Low-Cost Biotech Stocks With High Levels of Growth - August 21, 2018
These five biotech stocks balance low valuation with high growth and a track record of profits. Continue…
-
7 Rebound Stocks Coming Back From the Dead - July 27, 2018
Sometimes seemingly deadbeat stocks still have more life left in them despite what the Street thinks. Here are seven rebounding stocks that have the support of top analysts. Continue…
-
5 Pharmaceutical and Biotech Stocks to Consider for July - July 6, 2018
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar. Continue…
-
3 Big Stock Charts for Friday: Sherwin-Williams, Regeneron and Allstate - June 29, 2018
These three stock charts have the makings and markings of trade set-ups. Here's why, and how to best play them in this unusual environment. Continue…
-
The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear - June 7, 2018
Regeneron trades at just 25.5 times earnings, despite 20% growth and an ability to bring as much as one-third of revenue to the bottom line. With pharma no longer out of fashion, buy REGN stock before the market pushes it higher. Continue…
-
Tread Very Carefully When Investing in AnaptysBio Inc - March 28, 2018
ANAB is up on positive clinical studies posted in the last few months. But the small sample size and risks ahead could hurt the stock in the near term. Continue…
-
10 Stocks to Ride Out the Market Storm - February 6, 2018
Put these tickers on a list of stocks to buy here in the midst of market-wide carnage. They're likely to recover first and best once the selloff settles. Continue…
-
9 More Stocks Still Growing Faster Than Amazon - January 2, 2018
If you're looking for growth, Amazon.com isn't your only investment choice. These names are on a tear as well, and could be worthy additions to your portfolio. Continue…
-
Lackluster Quant Score Penalize Regeneron Pharmaceuticals (REGN) Rating - December 11, 2017
Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. The methods for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 6 months. Continue…
